A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

Clinical trial NCT00148486 · COMPLETED

Trial details

NCT number: NCT00148486
Sponsor: Boehringer Ingelheim
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Parkinson Disease

Start date: 2003-06-01
Primary completion: 2005-03-01
Enrollment: 261

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.